WebNews

Please enter a web search for web results.

NewsWeb

pharmaphorum
pharmaphorum. com > oncology > asco-2026-abbvie-adcs-chemotherapy-and-future-oncology

ASCO 2026: Abb Vie on ADCs, chemotherapy, and the future of oncology

13+ hour, 11+ min ago  (248+ words) For years, antibody-drug conjugates (ADCs) have been positioned as an important addition to the oncology toolkit. But, could they eventually replace chemotherapy altogether? At ASCO 2026 in Chicago, Pedro Valencia, vice president of asset strategy leadership for oncology at Abb Vie,…...

Symbols: nyse:abbv,btc-usd
pharmaphorum
pharmaphorum. com > news > which-biotechs-have-raised-new-vc-financing-week

Which biotechs have raised new VC financing this week?

18+ hour, 11+ min ago  (381+ words) Our latest roundup of venture capital financings in the biotech sector includes solid eight-figure rounds for Triveni, Cellares, HMNC, Vedana, and Neion Bio. Contract cell therapy manufacturer, Cellares, has made its already supersized fourth-round financing even bigger, raising another $50 million…...

Symbols: nasdaq:vrdn
pharmaphorum
pharmaphorum. com > news > us-launches-probe-german-underpayment-medicines

US launches probe of German 'underpayment' for medicines

17+ hour, 5+ min ago  (443+ words) The Trump administration has started an investigation into what it claims could be "persistent underpayment" for innovative medicines by Germany, raising the threat of punitive tariffs. The Section 301 investigation launched by US Trade Representative Jamieson Greer comes despite the US-EU…...

Symbols: btc-usd
pharmaphorum
pharmaphorum. com > news > fda-experts-endorse-modernas-mrna-seasonal-flu-shot

FDA experts endorse Moderna's m RNA seasonal flu shot

18+ hour, 27+ min ago  (660+ words) Moderna has moved a little closer to US approval of its new m RNA-based seasonal influenza vaccine, m Flusiva, after an FDA expert panel unanimously concluded it was safe and effective. The Vaccines and Related Biological Products Advisory Committee (VRBPAC)…...

Symbols: nasdaq:mrna
pharmaphorum
pharmaphorum. com > oncology > liquid-biopsy-and-future-tumour-agnostic-treatments

Liquid biopsy and the future of tumour-agnostic treatments

20+ hour, 12+ min ago  (335+ words) Master protocols can also be used in umbrella trials to stratify a single cancer type into distinct molecular subgroups to evaluate multiple targeted therapies simultaneously, while platform trials, such as Combo MATCH, extend this framework through perpetual, adaptive designs to…...

Symbols: nasdaq:repl
pharmaphorum
pharmaphorum. com > news > biogen-pens-1bn-deal-buy-immunology-biotech-raythera

Biogen pens $1bn deal to buy immunology biotech Ray Thera

2+ day, 1+ hour ago  (533+ words) Ray Thera co-founders Qing Dong and Gene Hung are serial biotech entrepreneurs, forming and selling Fron Thera, Xin Thera, and now Ray Thera. Biogen has dipped its toe into the M&A waters once again, agreeing to buy San Diego-based…...

Symbols: nasdaq:biib
pharmaphorum
pharmaphorum. com > rd > medical-education-bridging-science-and-clinical-practice

Medical education: Bridging science and clinical practice

2+ day, 12+ hour ago  (803+ words) Emily Harrison: Medical education plays a critical role in translating scientific evidence into practical clinical action. Awareness alone does not change patient outcomes. Clinicians need to understand not only the data, but also how to apply it within the realities…...

Google News
pharmaphorum. com > news > uniqure-sets-course-us-filing-huntington-gene-therapy

uni Qure sets course to US filing for Huntington gene therapy

2+ day, 15+ hour ago  (483+ words) uni Qure has agreed with the FDA that it can proceed with a marketing application for Huntington's disease gene therapy AMT-130, using data that it already has on hand, rather than running another trial. The FDA refused to accept uni…...

Symbols: nasdaq:qure
pharmaphorum
pharmaphorum. com > news > msd-steps-out-protillion-510m-ai-shindig

MSD steps out with Protillion in $510m+ AI shindig

2+ day, 16+ hour ago  (502+ words) MSD has formed a partnership with Protillion Biosciences, worth upwards of $510 million, that will focus on using the AI specialist's 'lab-in-the-loop' platform to discover multiple new therapeutics. Lab-in-the-loop approaches are gaining traction for AI-powered drug discovery at pharma companies, and…...

Symbols: nasdaq:msft
pharmaphorum
pharmaphorum. com > news > moderna-builds-commercial-muscle-new-launches-loom

Moderna builds commercial muscle as new launches loom

2+ day, 17+ hour ago  (536+ words) Moderna is hoping to launch three new vaccines in the next couple of years " including a flu shot that will come in front of an FDA advisory committee tomorrow " and has started building up its commercial operation in anticipation. To…...

Symbols: nasdaq:mrna